|
Sign In to gain access to subscriptions and/or personal tools.
|
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis
G M Liuzzi
Department of Biochemistry and Molecular Biology, University of Bari, Bari, Italy, m.g.liuzzi{at}biologia.uniba.it
M Trojano
Department of Neurology and Psychiatric Sciences, University of Bari, Bari, Italy
M Fanelli
Department of Hygiene, University of Bari, Bari, Italy
C Avolio
University of Foggia, Italy
A Fasano
Department of Biochemistry and Molecular Biology, University of Bari, Bari, Italy
P Livrea
Department of Neurology and Psychiatric Sciences, University of Bari, Bari, Italy
P Riccio
Department of Biology D.B.A.F., University of Basilicata, Potenza, Italy
Matrix metalloproteinase-9 (MMP-9) was detected by zymography and enzyme-linked immunosorbent assay (ELISA) in matched serum and cerebrospinal fluid (CSF) samples from patients with neurological diseases. Patients with relapsing-remitting multiple sclerosis (RR-MS) had serum and CSF MMP-9 levels comparable to those from patients with inflammatory neurological diseases (INDs), but higher than patients with non-inflammatory neurological diseases (NINDs) and healthy donors (HDs). MMP-9 increased in active RR-MS in comparison with inactive RR-MS implying that MMP-9 in MS is related with clinical disease activity. A correlation between the CSF/serum albumin (QAlb) and CSF/serum MMP-9 (QMMP-9) was observed in IND and NIND but not in RR-MS patients, indicating that CSF MMP-9 levels in NIND and IND patients could be influenced by serum MMP-9 and blood-brain barrier (BBB) permeability properties. MS patients had higher values of QMMP-9:QAlb (MMP-9 index) than IND and NIND patients suggesting that in MS the increase in CSF MMP-9 could be due to intrathecal synthesis of MMP-9. A significant inverse correlation was found between MMP-9 and its endogenous inhibitor TIMP-1 in RR-MS indicating that in MS patients both the increase in MMP-9 and the decrease in TIMP-1 serum levels could contribute to BBB disruption and T-lymphocyte entry into the CNS.
Key Words: blood-brain barrier cerebrospinal fluid intrathecal synthesis matrix metalloproteinases MMP-9 index multiple sclerosis serum TIMP-1
Multiple Sclerosis, Vol. 8, No. 3,
222-228 (2002)
DOI: 10.1191/1352458502ms800oa

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y Benesova, A Vasku, H Novotna, J Litzman, P Stourac, M Beranek, Z Kadanka, and J Bednarik
Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis
Multiple Sclerosis,
March 1, 2009;
15(3):
316 - 322.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial
Arch Neurol,
February 1, 2008;
65(2):
199 - 204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Hachinski, C. Iadecola, R. C. Petersen, M. M. Breteler, D. L. Nyenhuis, S. E. Black, W. J. Powers, C. DeCarli, J. G. Merino, R. N. Kalaria, et al.
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
Stroke,
September 1, 2006;
37(9):
2220 - 2241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis
Multiple Sclerosis,
June 1, 2006;
12(3):
294 - 301.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette
Lipoic acid in multiple sclerosis: a pilot study
Multiple Sclerosis,
April 1, 2005;
11(2):
159 - 165.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Liuzzi, T. Latronico, A. Fasano, G. Carlone, and P. Riccio
Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment
Multiple Sclerosis,
June 1, 2004;
10(3):
290 - 297.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Liuzzi, C. M. Mastroianni, T. Latronico, F. Mengoni, A. Fasano, M. Lichtner, V. Vullo, and P. Riccio
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia
Brain,
February 1, 2004;
127(2):
398 - 407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Martin, B. Z. Moyer, M. C. Pape, B. Starcher, K. J. Leco, and R. A. W. Veldhuizen
Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis
Am J Physiol Lung Cell Mol Physiol,
December 1, 2003;
285(6):
L1222 - L1232.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|